Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2025

Jul 7, 2025

32973_dirs_2025-07-07_4bbb3d0a-d5e3-4910-ae6a-5d1cff2adb14.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2025-07-02

Reporting Person: HAUSMAN DIANA (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-07-02 Class A Common Stock P 2500 $3.5956 Acquired 2500 Direct
2025-07-02 Class A Common Stock P 3000 $3.6245 Acquired 3000 Indirect